title: [Tavanik effectiveness and safety in the treatment of urinary tract infection complications].
abstract: 20 patients with complicated urinary infection (CUI) have been treated with levofloxacine (tavanik) for 10 days in a single daily dose 250 mg. They were compared with 23 acute pyelonephritis patients given ciprofloxacin in a dose 1 g/day. None of the patients had purulent inflammation or was treated with antibacterial drugs. The response to tavanik and its safety were good or very good in 95% patients. With ciprofloxacin the same results were achieved in 88% patients. 3 patients failed this treatment. 2 patients developed purulent pyelonephritis and were operated. The number and intensity of side effects were higher were less in the tavanik group. Thus, tavanik, a new antibacterial drug from fluoroquinolone group, is effective and low-toxic in complicated infection of the urinary tracts.
authors.forename: O B
authors.initials: OB
authors.lastname: Loran
authors.forename: D Iu
authors.initials: DIu
authors.lastname: Pushkar'
authors.forename: P I
authors.initials: PI
authors.lastname: Rasner
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D015242:Ofloxacin